Omada Health Reports Third Quarter 2025 Results

Core Insights - Omada Health reported a revenue of $68 million for Q3 2025, representing a 49% increase year-over-year, with total members reaching 831,000, a 53% growth compared to Q3 2024 [1][7][8] - The company achieved a significant reduction in net loss, reporting a net loss of $3 million compared to $9 million in Q3 2024, and recorded its first quarter of positive adjusted EBITDA at $2 million [1][8] - Omada announced a new GLP-1 prescribing offering aimed at enhancing member health outcomes and providing cost savings for customers [1][7][8] Financial Performance - Revenue for Q3 2025 was $68 million, up 49% from $45.5 million in Q3 2024 [7][8] - Gross margin improved to 66%, up from 63% in the same quarter last year, with a non-GAAP gross margin of 68% [8] - Adjusted EBITDA was reported at $2 million, a significant improvement from an adjusted EBITDA loss of $5 million in Q3 2024 [8] Member Growth and Offerings - Total members increased to 831,000, marking a 53% growth compared to the previous year [7] - The new GLP-1 prescribing offering will integrate Omada's behavior change program with medication management for anti-obesity medications [7] - The company published its 30th peer-reviewed manuscript, demonstrating cost savings from its Joint & Muscle Health program and showing that members largely maintained their weight one year after discontinuing GLP-1 therapy [7] Cash Position and Financial Outlook - Cash and cash equivalents stood at $199 million as of September 30, 2025 [8] - For the full year 2025, Omada expects revenue in the range of $251.5 million to $254.5 million, an increase from the previous range of $235 million to $241 million [8]